GILD Gilead Sciences
- 79.520
- +0.960+1.22%
Gilead Sciences News
Express News | Gilead : Jefferies Raises Target Price to $95 From $90
Gilead Sciences Trades in the Green for Seventh Straight Session
Decoding Gilead Sciences's Options Activity: What's the Big Picture?
Is the rebound fading? Goldman Sachs: Hedge funds are selling stocks at the fastest pace in more than two years.
In August, 'smart money' is selling global equities at the fastest pace since March 2022, with the most net selling in North America. Hedge funds are skeptical of the sustainability of the stock market rebound, and geopolitical concerns continue to be worrying. The 'fly' of the economic situation may soon hit the glass windshield.
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here Is What You Need to Know
Gilead Sciences: A Balanced Hold Rating Amidst Growth Prospects and Market Challenges
Analysts' Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD) and Premier (PINC)
Wells Fargo Maintains Gilead Sciences(GILD.US) With Hold Rating, Maintains Target Price $78
Gilead Sciences to Present at Upcoming Investor Conferences
The 20 Most Popular Mutual Fund Increases During 2Q - Goldman Sachs
FTC Says FDA Biosimilar Guidance Would Increase Competition, Lead to Lower Prices
How To Earn $100 Per Month From Gilead Sciences Stock
Peering Into Gilead Sciences's Recent Short Interest
Gilead Sciences: "One of Best Employers for Women" by Forbes
Building a Bridge to a Healthier World for Youth in Africa With Gilead Sciences
Mpox Outbreak Has World on High Alert. What to Know
Gilead (GILD) Obtains FDA Approval for PBC Drug Livdelzi
Express News | Pantherx Rare Partnering With Gilead Sciences For Distribution Of Livdelzi
Express News | Pantherx® Rare Partnering With Gilead Sciences, Inc. for Distribution of Livdelzi®
Analysis
Price Target
No Data
